(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 November 2013 (14.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/169338 A1

(51) **International Patent Classification**:
A61K 38/16 (2006.01) *C07K 1/00* (2006.01)

(21) **International Application Number**:
PCT/US2013/030179

(22) **International Filing Date**:
11 March 2013 (11.03.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/645,686 11 May 2012 (11.05.2012) US

(71) **Applicants**: **MEDIMMUNE, LLC** [US/US]; One Medimmune Way, Gaithersburg, MD (US). **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge, CambCambridgeshire CB21 6GH (GB).

(72) **Inventors**: **MINTER, Ralph**; c/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **DOUTHWAITE, Julie**; c/o Medimmune Limited, Milstein Building, Granta Park, Cambridge, CB21 6GH (US). **MOISAN, Jacques**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **BOWEN, Michael**; c/o Medimmune LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **RUST, Steve**; c/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **PRIVEZENTZEV, Cyril**; c/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB).

(74) **Agent**: **CARROLL, Shannon**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/169338 A1

(54) **Title**: CTLA-4 VARIANTS

(57) **Abstract**: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.